BioSpace News Archive

The Symposium will be held virtually from May 31 to June 3, 2021 and is sponsored by the Canadian Society for Pharmaceutical Sciences.

The first-ever single-incision navigated hip-revision surgery was performed with Naviswiss hip navigation system, developed by Naviswiss U.S. The technology allowed for accurate and precise component positioning without the need for additional incisions, as is typically required in a navigated surgery.

Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced the publication in Frontiers in Immunology of its positive long-term Overall Survival (OS) data from the Phase I trial evaluating the Company’s universal cancer vaccine, UV1, in combination with checkpoint inhibitor ipilimumab in patients with metastatic malignant melanoma

Spectrum Solutions, LLC today announced Bill Phillips, the company’s Chief Operating Officer, accepted an invitation to join the Board of Governors of the Salt Lake Chamber

Strategic partnership with OSF HealthCare underscores VIDA’s ongoing dedication to raising the standard of care for patients with lung and respiratory diseases

Patents and patent applications provide additional coverage for the company’s shockwave and ultrasound technologies in medical and non-medical fields

SOTIO , a clinical stage immune-oncology company owned by PPF Group, today announced the presentation of a virtual poster at the 2021 ASCO Annual Meeting.

MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference on Tuesday, May 18, 2021 at 4:15 pm.

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its first quarter 2021 financial results on Friday, May 14, 2021 before the open of US markets.

Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, and Numinus Wellness Inc. (“Numinus”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, have met another early milestone in the development of an initial all natural psilocybin extract.